Four New Studies Featuring Zio® by iRhythm to be Presented at ACC.23/WCC
March 02 2023 - 8:30AM
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health
company focused on creating trusted solutions that detect, predict,
and prevent disease, will have the results of four studies
presented by leading clinical investigators at the American College
of Cardiology’s Annual Scientific Session Together With the World
Congress of Cardiology (ACC.23/WCC) from March 4-6, 2023, in New
Orleans, LA.
These studies further strengthen iRhythm’s body of clinical and
scientific evidence to differentiate its Zio suite of products and
services. New research will include data from the CAMELOT study,
the first and largest study of its kind1,2 to evaluate diagnostic
yield, time to clinical diagnosis, retest rates, and healthcare
resource utilization among different cardiac monitoring services,
and will also detail initial clinical experience with the next
generation of iRhythm’s ECG patch, the Zio monitor, which will be
commercially available later this year.
Clinical findings will be presented at the conference during the
times listed below.
Saturday, Mar. 4
- 1:30 – 1:40 p.m. CDT, exact time may vary: “Initial
Real World And Clinical Experience Of The Next Generation
Ambulatory ECG Zio Monitor: Implications For Standard And Extended
Wear Monitoring.” Presenter: Dr. Jay Alexander,
cardiologist, NorthShore University HealthSystem and medical
director, iRhythm.
- 1:45 – 2:30 p.m. CDT: “Prevalence And Prognostic Value
Of Ventricular Tachycardia On Ambulatory ECG Monitoring.”
Presenter: Dr. Krishna Pundi, fellow in cardiovascular medicine,
Stanford University School of Medicine.
Sunday, Mar. 5
- 1:45 – 2:30 p.m. CDT: “CAMELOT: Comparative
Effectiveness Of Ambulatory Monitors For Arrhythmia Diagnosis: A
Retrospective Analysis Of Medicare Beneficiaries.”
Presenter: Dr. Suneet Mittal, associate chair of cardiovascular
services and director of electrophysiology, Valley Health
System.
Monday, Mar. 6
- 12:45 – 1:30 p.m. CDT: “Comparison Of Patch Versus
Multi-electrode Cardiac Monitoring For The Detection Of
Arrhythmias: The COMPARE Study.” Presenter: Dr. Lohit
Garg, assistant professor, University of Colorado Anschutz School
of Medicine.
To join iRhythm at ACC.23/WCC, please visit booth #129 to learn
more. Clinicians and health care professionals can also RSVP for an
educational event, “Cardiac Monitoring: Clinical Challenges,
Evidence Gaps, and Patient Outcomes,” here.
About iRhythm Technologies, Inc.iRhythm is a
leading digital health care company that creates trusted solutions
that detect, predict, and prevent disease. Combining wearable
biosensors and cloud-based data analytics with powerful proprietary
algorithms, iRhythm distills data from millions of heartbeats into
clinically actionable information. Through a relentless focus on
patient care, iRhythm’s vision is to deliver better data, better
insights, and better health for all.
____________________________
1 Reynolds et al. Comparative Effectiveness Of Ambulatory
Monitors For Arrhythmia Diagnosis: A retrospective analysis of
Medicare beneficiaries managed with ambulatory cardiac monitors
between 2017 and 2019. Accepted for ACC.23 presentation, presented
in New Orleans, LA.
2 Data on file. iRhythm Technologies, 2023.
Investor Relations Contact:Stephanie
Zhadkevich(919) 452-5430investors@irhythmtech.com
iRhythm Media Contact:Morgan Mathis(310)
528-6306irhythm@highwirepr.com
iRhythm Technologies (NASDAQ:IRTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
iRhythm Technologies (NASDAQ:IRTC)
Historical Stock Chart
From Apr 2023 to Apr 2024